Bosulif (Bosutinib) - Chronic Myeloid Leukemia
Bosulif (Bosutinib) is a third generation tyrosine kinase inhibitor. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis (cell death). Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I.
SITES
Bosutinib by Bosutinib.org
Bosulif (Bosutinib) by Pfizer.com
Bosulif (Bosutinib) for Professionels by Pfizer.com
Bosulif (Bosutinib) by Pfizer.com
Bosulif (Bosutinib) for Professionels by Pfizer.com
FORUMS
Bosutinib CML Drug Development Update by LLS discussion Boards
The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia by LLS discussion Boards
Bosutinib CML Drug Development Update by LLS discussion Boards
The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia by LLS discussion Boards
ARTICLES
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
January 19, 2013, Pipelinereview.com
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
January 18, 2013, Pfizer Press Releases
Bosutinib in CML Cleared for Approval in Europe
January 18, 2013, Medscape
Pfizer's Bosulif set for greater sales with EMA approval
January 18, 2013, Fierce Pharna
Pfizer, Novartis win EU nods for new leukemia, eye drugs
January 18, 2013, FierceBiotech
Bosutinib a New Option for Chronic Myeloid Leukemia
December 2012, Clinical Oncology
FDA approves orphan drug for CML
October 1, 2012, HemOnc Today
FDA Approves Bosutinib (Bosulif) for Chronic Myeloid Leukemia (CML)
September 5, 2012, Cancer Network
Bosutinib tablets for chronic myelogenous leukemia
September 5, 2012, Foodconsumer
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial.
September 4, 2012, PublMed.gov
Pfizer Wins Approval for Drug to Treat Type of Leukemia
September 4, 2012, Bloomberg
The FDA (U.S. Food and Drug Administration) approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML)
September 4, 2012, U.S. Food and Drug Administration
U.S. Food and Drug Administration Approves BOSULIF® (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)
September 4, 2012, Pfizer Press Releases
Mismarketed Chemical Causes Concern
May 13, 2012, The Scientist
January 19, 2013, Pipelinereview.com
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
January 18, 2013, Pfizer Press Releases
Bosutinib in CML Cleared for Approval in Europe
January 18, 2013, Medscape
Pfizer's Bosulif set for greater sales with EMA approval
January 18, 2013, Fierce Pharna
Pfizer, Novartis win EU nods for new leukemia, eye drugs
January 18, 2013, FierceBiotech
Bosutinib a New Option for Chronic Myeloid Leukemia
December 2012, Clinical Oncology
FDA approves orphan drug for CML
October 1, 2012, HemOnc Today
FDA Approves Bosutinib (Bosulif) for Chronic Myeloid Leukemia (CML)
September 5, 2012, Cancer Network
Bosutinib tablets for chronic myelogenous leukemia
September 5, 2012, Foodconsumer
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial.
September 4, 2012, PublMed.gov
Pfizer Wins Approval for Drug to Treat Type of Leukemia
September 4, 2012, Bloomberg
The FDA (U.S. Food and Drug Administration) approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML)
September 4, 2012, U.S. Food and Drug Administration
U.S. Food and Drug Administration Approves BOSULIF® (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)
September 4, 2012, Pfizer Press Releases
Mismarketed Chemical Causes Concern
May 13, 2012, The Scientist
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
April 12, 2012, PublMed
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
February 27, 2012, Journal Blood
BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO Post
Expert Point of View: BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO POST
April 12, 2012, PublMed
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
February 27, 2012, Journal Blood
BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO Post
Expert Point of View: BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO POST
Bosutinib Versus Imatinib (CML) Follow Up Study - Interview with Carlo Gambacorti-Passerini, MD, Professor of Internal Medicine VIDEO
December 2011,www.oncology.tv
Faster Response Rates in CML with Bosutinib
June 15, 2011, MedscapeToday
Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference
STUDY 200: Study Evaluating Bosutinib in Philadelphia Chromosome Positive Leukemia
June 3, 2011, Pfizer Oncology
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia VIDEO
February 18, 2011, ecancerTV
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
January 2011, ClinicalTrialFeeds.org
Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 4, 2010, Medical NewsToday
December 2011,www.oncology.tv
Faster Response Rates in CML with Bosutinib
June 15, 2011, MedscapeToday
Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference
STUDY 200: Study Evaluating Bosutinib in Philadelphia Chromosome Positive Leukemia
June 3, 2011, Pfizer Oncology
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia VIDEO
February 18, 2011, ecancerTV
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
January 2011, ClinicalTrialFeeds.org
Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 4, 2010, Medical NewsToday
.
